TroFuse-010
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- NCT06312176 ↗
- Recruiting
- Merck Sharp & Dohme LLC
- Standard
We haven't built an HCP commentary report on TroFuse-010 (sacituzumab tirumotecan, pembrolizumab and 4 more in Breast Neoplasms) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TroFuse-010 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 10 | |
| YouTube | 3 | |
| Podcasts | 3 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Breast Neoplasms
- Interventions
- Sacituzumab tirumotecan; Pembrolizumab; Paclitaxel; Nab-paclitaxel; Capecitabine; Liposomal doxorubicin
- Arms
- Arm A: Sacituzumab tirumotecan · Experimental
- Arm B:Pembrolizumab + Sacituzumab tirumotecan · Experimental
- Arm C: Treatment of Physician's Choice (TPC) · Active comparator
- Enrollment
- 1,200 (estimated)
- Primary outcomes
- Progression-Free Survival (PFS) ( sacituzumab tirumotecan versus treatment of physician's choice [TPC]; pembrolizumab + sacituzumab tirumotecan versus TPC)
- PFS (Sacituzumab tirumotecan + pembrolizumab versus TPC)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Apr 14, 2024
- Primary completion
- Jul 11, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06312176 · updated Oct 13, 2026